

EUonQoL: meauring what matters for cancer patients and survivors in Europe

Project overview

Cinzia Brunelli

Fondazione IRCCS Istituto Nazionale Tumori- Milano

Chairperson of the OECI Cancer Outcome Research WG









Conflict of Interest disclosure

I do not have any actual or potential conflict of interest in relation to this presentation.

Talk outline



- The «origins» of the project
- Project overview
- The pan-European pilot survey



Patient quality of life and cancer care

- Survival, recurrence as well as other clinical and process indicator are relevant cancer care outcomes
- However patient-centred outcomes, such as health-related quality of life (HRQoL-PROMs), functional impairment, pain, psycho-social aspects, experience of care, are factors of great significance for patients.



Patient quality of life and cancer care

Clinical trials and real-world data have shown the positive effects of routine PROMs assessment on patient wellbeing, use of health care resources and on survival.

Kotronoulas 2016 - Basch 2016, Denis 2017 - Lizée 2019 Barberal JOP 2020, Barberal Cancer med 2020, Barberal BMJ SUPP Pall Care 2020 Fjell 2020, Absolom 2021, Maguire 2021 Mir 2022, Basch 2022



....but

full implementation of QoL assessment in routine oncology practice is not yet part of standard of care.

health care systems and cancer control programs do not take into consideration QoL outcomes when devising clinical, societal, and healthcare policymaking systems.





OECI Cancer Outcome Research Working Group

The main aim of the COR-WG is to respond to this need and establish and coordinate a network of clinical cancer centers adopting common procedures for the routine collection and sharing of PROM data.

EUonQoL project constitutes the first step in this direction



In parallel with prevention and treatment of cancer, the improvement or preservation of patients quality of life is one of the three pillars of the EC Mission on Cancer.











OECI Cancer Outcome Research Working Group

OECI Working Groups

OECI One-Shot Project
OECI initiative on strategies
of implementation of PROMs and
PREMs in oncology clinical practice,
research & benchmarking

Giovanni Apolone^{1,2}, Cinzia Brunelli¹, Alice Gallivanone¹, and Augusto Caraceni¹ 1. Fondazione IRCCS Istituto Nazionale Tumori-Milano

2. Organisation of European Cancer Institutes





Chairperson

Cinzia Brunelli

Outcome research has been defined as the study of the final results of health care interventions, and is aimed at providing all stakeholders the scientific evidence to base their decisions. Clinicians have to select effective and non-harmful treatments for their patients, policy-makers are interested in identifying cost-ineffective interventions/services, while patients need to make informed treatment choices.

A step forward PROmics

Cinzia Brunelli¹, Giovanni Apolone¹ and Augusto Caraceni¹
1. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano





HORIZON-MISS-2021-CANCER-02-02



EN

Horizon Europe

Work Programme 2021-2022

12. Missions

(European Commission Decision C(2021)9128 of 15 December 15

Develop and validate a set of quality of life and patient preference measures for cancer patients and survivors

HORIZON-MISS-2021-CANCER-02-02: Develop and validate a set of quality of life and patient preference measures for cancer patients and survivors

Specific conditions		
Expected EU contribution per project	The Commission estimates that an EU contribution of around EU 11.00 million would allow these outcomes to be addresse appropriately. Nonetheless, this does not preclude submission an selection of a proposal requesting different amounts.	
Indicative budget	The total indicative budget for the topic is EUR 11.00 million.	
Type of Action	Research and Innovation Actions	
Legal and financial set-up of the Grant Agreements	ap of the Grant apply:	

Especially through the 'European Guidelines and Quality Assurance Schemes for Breast, Colorectal and Cervical Cancer Screening and Diagnosis', and the 'European Cancer Information System (ECIS)', see

https://knowledge4policy.ec.europa.eu/cancer en



⁹⁸ https://eithealth.eu/who-we-are/

⁹⁹ https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32021R0694&qid=1623079930214



EUonQoL project

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe

Is aimed at developing, validating and disseminating the European Oncology Quality of Life toolkit (EUonQoL-Kit) among European cancer patients and survivors.

The EUonQoL – Kit




It will be a **new unified system for the self-assessment of quality of life** in cancer patients undergoing treatment, in cancer survivors and in patient palliative care phase. It will be:

- developed from the patient perspective
- available in several European languages
- Available in static and dynamic versions (computer adaptive testing)
- digitally administrable
- psychometrically sound
- applicable in future periodic surveys for health policy intervention evaluation

EUonQoL objectives






Participatory research



The overall project will be based on participatory co-design research principles through the involvement of a representative panel of stakeholders, including patients and their caregivers.







	WP Title	Lead and co-lead Participants
WP1	Ethics requirements	INT
WP2	Involvement of stakeholders and patients	NIVEL/ECO
WP3	Review of existing HRQoL databases, measures & item libraries	EORTC/IMIM
WP4	Development of the EUonQoL-Kit	UNIVLEEDS/UMIL
WP5	Cross-cultural determinants of the QoL and linguistic and cultural adaptation of EUonQoL-Kit	IEO/SPOREDATA
WP6	Digital tools for data collection	DIGICORE/RH
WP7	EUonQoL-Kit Pilot Survey	INT/OECI
WP8	Implementation/Exploitation	OUS/UNICANCER
WP9	Dissemination/Communication	OECI/ECO
WP10	Project Management/Coordination	INT





Coordinator

Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy

13 Countries 26 Partner/Affiliated/Associated Partner

Austria Medical University of Innsbruck (MUI)

Belgium Digital Institute For Cancer Outcomes Research (DIGICORE)

European Organisation for Research and Treatment of Cancer AISBL (EORTC)

European Association of Palliative Care (EAPC)

European Cancer Organisation (ECO)

Organisation of European Cancer Institutes (OECI)

Bulgaria Association of Cancer Patients and Friends (APOZ)

Denmark Region Hovedstaden (RH) Estonia Sporedata OÜ (SPOREDATA)

France Institut Curie (CURIE)

Norway

Institut Gustave Roussy (GR) Unicancer (UNICANCER)

Germany Deutsches Krebsforschungszentrum Heidelberg (DFKZ)

Italy Alleanza Contro il Cancro (ACC)

Federazione Italiana delle Associazioni di Volontariato in Oncologia (FAVO)

Istituto Europeo di Oncologia (IEO)

Istituto Nazionale Tumori Fondazione Pascale (INT-NA)

Istituti Fisioterapici Ospitalieri (IFO)
Universita Degli Studi di Milano (UMIL)
Oslo Universitetssykehus Hf (OUS)
Asociatiilor Bolnavilor de Cancer (FABC)

Romania Asociatiilor Bolnavilor de Cancer (FABC)
Spain Fundacio Institut Mar d'Investigacions Mediques (IMIM)
The Netherlands Stichting Het Nederlands Kanker Instituut-Anton (NKI)

Stichting Nederlands Instituut Voor Onderzoek Van De Gezondheidszorg (NIVEL)

United Kingdom University of Leeds (UNIVLEEDS)

Leeds Teaching Hospital Trust's (LTHT)



Project Data

•	Starting date:	1 January 2023
---	----------------	----------------

- End date: 31 December 2026
- Duration:
 48 months (M24 tool validation)
- Total cost including UK: € 10.999.810,76
- EU financial contribution: € 10.607.311,00
- Number of beneficiaries:
- Number of affiliated entities:

Pilot survey participants

- Number of beneficiaries involved in the pilot survey: 10
- Number of other cancer centres:



	WP Title	Lead and co-lead Participants
WP1	Ethics requirements	INT
WP2	Involvement of stakeholders and patients	NIVEL/ECO
WP3	Review of existing HRQoL databases, measures & item libraries	EORTC/IMIM
WP4	Development of the EUonQoL-Kit	UNIVLEEDS/UMIL
WP5	Cross-cultural determinants of the QoL and linguistic and cultural adaptation of EUonQoL-Kit	IEO/SPOREDATA
WP6	Digital tools for data collection	DIGICORE/RH
WP7	EUonQoL-Kit Pilot Survey	INT/OECI
WP8	Implementation/Exploitation	OUS/UNICANCER
WP9	Dissemination/Communication	OECI/ECO
WP10	Project Management/Coordination	INT




	WP Title	Lead and co-lead Participants
WP1	Ethics requirements	INT
WP2	Involvement of stakeholders and patients	NIVEL/ECO
WP3	Review of existing HRQoL databases, measures & item libraries	EORTC/IMIM
WP4	Development of the EUonQoL-Kit	UNIVLEEDS/UMIL
WP5	Cross-cultural determinants of the QoL and linguistic and cultural adaptation of EUonQoL-Kit	IEO/SPOREDATA
WP6	Digital tools for data collection	DIGICORE/RH
WP7	EUonQoL-Kit Pilot Survey	INT/OECI
WP8	Implementation/Exploitation	OUS/UNICANCER
WP9	Dissemination/Communication	OECI/ECO
WP10	Project Management/Coordination	INT



EUonQoL-Kit pan European pilot survey.

An overall sample of 4,000 among cancer patients in treatment, cancer survivors and patients in palliative care phase, will be enrolled in a cooperative network of European cancer centres







Primary

To assess validity and reliability of the EUonQoL-Kit among cancer patients and survivors in Europe (psychometric validation)





Secondary

- 1. Assess the acceptability of the EUonQoL-Kit and reasons for refusal, including patient burden in filling in the questionnaire
- 2. Validate the Computer Adaptive Testing (CAT) version of the EUonQoL-Kit
- 3. Provide estimates of QoL across different European countries
- 4. Analyse socio-demographic and clinical factors potentially associated to QoL in European cancer patients and survivors
- 5. Analyse QoL inequalities across clusters of populations, countries, and healthcare systems



Study design

Observational multicentre cross-sectional study, focused on the validation of the newly developed EUonQoL-Kit.

Study population



Patients in one of the following conditions:

A. In treatment

B. Survivors

C. In need of PC

Detailed definitions are provided





Inclusion

- Age 18 years or more
- Present or past histologically confirmed diagnosis of solid tumor or haematological malignancy
- Being in one of the 3 conditions:
 A) In treatment; B) Survivors; C) In need of PC
 - , in treatment, by sarvivors, e, in need of
- Written informed consent to the study

Exclusion

Cognitive impairment preventing the completion of the questionnaire

Study procedures

100

patients



Patient recruitment

Each centre will recruit 100 patients with pre-defined sub-groups

(at least 40 centres for expected minimum sample size of 4.000 patients)

A. In treatment 40 patients

B. Survivors30 patients

C. In need of PC 30 patients

Electronic version of EUonQoL-Kit

Where are we now



- Kick-off meeting on January 2023
- First investigator meeting end February 2023
- Preparatory tasks ongoing (agreements, ethical approvals...)
- Ad hoc preparatory meetings with centres will start from Autumn 2023.



EUonQoL Quality of Life in Oncology



About us ▼

Patients' voices

Results

News & Events



Our ambition



The project is aimed to contribute to the EU initiatives against cancer, by developing the European Oncology Quality of Life Toolkit (EUonQoL-kit), a patient-centred unified tool for the assessment of quality of life among cancer patients and survivors.

The EUonQoL- kit



The EUonQoL-Kit is a set of questionnaires, specifically designed for the selfassessment of quality of life at different disease phases, characterized by innovative features.

The partners



The EUonQoL project is based on a European network of research institutions, cancer centres, as well as scientific, professional, and patient representative organisations with the most relevant expertise in the field of quality-of-life research.

Read more >

EUonQoL

www.euongol.eu

Read more >

Read more >



EUonQoL expected impact



- Availability EUonQoL-Kit will be a system to identify patient needs and assess the impact of health care policies.
- Implementation and results dissemination through a wide stakeholder network will likely promote the routine use of PROMs in clinical practice.



 Routine collection of PROMs data will add patient perspectives within multiomics personalized oncology (... PROMICS), ultimately constitutes an important new opportunity in the progress toward patient-centred care.



The working group





Thank you for your attention



This project received funding from the European Union Horizon Europe Research and Innovation Programme Grant Agreement N. 101096362



Study procedures



